IL12A encodes the p35 subunit (also called IL-12p35) of interleukin-12 (IL-12), a heterodimeric cytokine critical for bridging innate and adaptive immunity. IL-12 is composed of the p35 subunit (encoded by IL12A) and the p40 subunit (encoded by IL12B), forming the bioactive IL-12p70. The gene is located on chromosome 3q25.33 and is expressed primarily in dendritic cells, macrophages, B cells, and other antigen-presenting cells.
Beyond its well-established role in immune regulation, IL-12 has emerged as an important player in neuroinflammation associated with neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
¶ Gene Structure and Expression
The IL12A gene spans approximately 20 kb and consists of 7 exons encoding the p35 subunit (253 amino acids). The gene is regulated by multiple promoters and enhancers that control its expression in different immune cell types.
- Immune cells: High expression in dendritic cells, macrophages, monocytes, and B cells
- Central nervous system: Low basal expression in astrocytes and microglia; upregulated in disease states
- Peripheral tissues: Variable expression in spleen, thymus, and lymphoid organs
IL12A expression is regulated by:
- Transcription factors: NF-κB, IRF family members, STAT4
- Epigenetic modifications: DNA methylation and histone acetylation
- Post-transcriptional regulation: miRNAs targeting IL12A mRNA
¶ Protein Structure and Function
The p35 subunit belongs to the helical cytokine family and contains:
- N-terminal signal peptide: Directs secretion
- Four-helix bundle core: Cytokine receptor binding domain
- C-terminal extension: Dimerization interface with p40
The functional IL-12 cytokine (IL-12p70) is a heterodimer:
- p35 subunit: Provides the receptor-binding specificity
- p40 subunit: Contains the second receptor-binding site and controls signaling
The IL-12p70 binds to the IL-12 receptor (IL-12Rβ1/IL-12Rβ2) on T cells and NK cells, activating STAT4 and downstream gene expression.
- Th1 differentiation: IL-12 promotes differentiation of naïve CD4+ T cells into Th1 cells
- IFN-γ production: Stimulates natural killer (NK) cells and T cells to produce interferon-gamma (IFN-γ)
- Cellular immunity: Enhances cytotoxic T lymphocyte (CTL) and NK cell activity
- Anti-tumor immunity: Promotes anti-tumor immune responses
In the CNS, IL-12 participates in neuroinflammatory processes:
- Microglial activation: Modulates microglial phenotype and cytokine production
- T cell recruitment: Attracts peripheral T cells to the CNS in neuroinflammation
- Cytokine cascade: Regulates production of other pro-inflammatory cytokines
IL-12 contributes to neuroinflammation in AD through multiple mechanisms:
- Microglial activation: IL-12 enhances microglial production of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6
- Chronic inflammation: Elevated IL-12 levels in AD brain tissue and cerebrospinal fluid correlate with disease severity
- Amyloid-β response: IL-12 may modulate microglial clearance of amyloid-β plaques
- Synaptic dysfunction: Pro-inflammatory cytokines induced by IL-12 can impair synaptic plasticity
In PD, IL-12 plays a role in dopaminergic neuron loss:
- Neuroinflammation: IL-12 is elevated in the substantia nigra and cerebrospinal fluid of PD patients
- Microglial activation: Chronic IL-12 signaling contributes to persistent microglial activation
- Dopaminergic toxicity: Inflammatory cytokines induced by IL-12 can damage dopaminergic neurons
- α-Synuclein pathology: IL-12 may influence α-synuclein aggregation and spread
IL-12 is implicated in ALS pathogenesis:
- Motor neuron vulnerability: Pro-inflammatory IL-12 signaling may contribute to motor neuron death
- Microgliosis: Enhanced microglial activation in ALS spinal cord
- T cell infiltration: IL-12 may promote inflammatory T cell responses in ALS
- Multiple Sclerosis: IL-12 is a key driver of Th1-mediated demyelination
- Frontotemporal Dementia: Neuroinflammatory IL-12 elevation observed
- Huntington's Disease: Elevated IL-12 in Huntington's disease brain
IL-12 represents a therapeutic target for neurodegenerative diseases:
Ustekinumab and other IL-12/23p40 antibodies (targeting the shared p40 subunit) are approved for psoriasis and IBD and have been explored in:
- Neuroinflammatory disorders: Potential for reducing chronic neuroinflammation
- AD clinical trials: Phase 1/2 trials investigating anti-IL-12/23 in AD
- PD: Investigational approaches targeting IL-12 signaling
- Anti-inflammatory compounds: Targeting IL-12 downstream effects
- Microglial modulation: Shifting microglial phenotype from pro-inflammatory to neuroprotective
- T cell regulation: Modulating Th1 responses in the CNS
- Complexity: IL-12 has both pro-inflammatory and immunoregulatory roles
- Blood-brain barrier: Therapeutic delivery to the CNS
- Timing: Optimal intervention window in disease progression
¶ Interactions and Signaling Pathways
IL-12 interacts with numerous cytokines relevant to neurodegeneration:
| Cytokine |
Interaction |
Effect |
| IFN-γ |
Synergistic |
Enhanced Th1 differentiation |
| IL-1β |
Additive |
Pro-inflammatory amplification |
| TNF-α |
Synergistic |
Neurotoxicity |
| IL-10 |
Antagonistic |
Anti-inflammatory counter-regulation |
| IL-23 |
Shared subunit |
Th17 differentiation |
- JAK-STAT pathway: IL-12 activates STAT4, STAT3, and STAT5
- NF-κB pathway: Downstream pro-inflammatory gene expression
- PI3K/AKT pathway: Cell survival signaling
- MAPK pathway: Cell proliferation and differentiation
- IL12A polymorphisms have been associated with susceptibility to autoimmune diseases
- Some variants may influence neurodegenerative disease risk, though evidence is limited
- IL-12 levels in cerebrospinal fluid may serve as neuroinflammatory markers
- IL-12p35 expression in peripheral blood mononuclear cells (PBMCs) correlates with disease activity
| Agent |
Target |
Status |
Indication |
| Ustekinumab |
IL-12/23p40 |
Approved |
Psoriasis, Crohn's |
| Briakinumab |
IL-12/23p40 |
Withdrawn |
Psoriasis |
| ABBV-951 |
IL-12 |
Investigational |
AD (preclinical) |
Key areas of active investigation include:
- Mechanism of action: Elucidating IL-12's precise role in neurodegenerative neuroinflammation
- Biomarker development: IL-12 as a CSF or blood marker for disease progression
- Therapeutic targeting: Developing brain-penetrant IL-12 modulators
- Cell-type specificity: Understanding IL-12 effects on neurons vs. glia
- Combination therapy: IL-12 modulation with other anti-inflammatory approaches